Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07160790

Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease

Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux(NERD) Disease: Double-blind, Randomized

Status
Not Yet Recruiting
Phase
Phase 3
Study type
Interventional
Enrollment
321 (estimated)
Sponsor
Onconic Therapeutics Inc. · Industry
Sex
All
Age
19 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This study aims to evaluate the efficacy and safety of JP-1366 in Patients with NERD

Conditions

Interventions

TypeNameDescription
DRUGJP-1366 + placebotaking JP-1366 + placebo
DRUGPlacebo + Placebotaking placebo + placebo

Timeline

Start date
2025-09-02
Primary completion
2026-06-30
Completion
2026-06-30
First posted
2025-09-08
Last updated
2025-09-08

Source: ClinicalTrials.gov record NCT07160790. Inclusion in this directory is not an endorsement.